Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02865850
Registration number
NCT02865850
Ethics application status
Date submitted
8/08/2016
Date registered
15/08/2016
Date last updated
18/07/2022
Titles & IDs
Public title
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
Query!
Scientific title
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION)
Query!
Secondary ID [1]
0
0
2016-000838-21
Query!
Secondary ID [2]
0
0
AKB-6548-CI-0016
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Blood
0
0
0
0
Query!
Anaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vadadustat
Treatment: Drugs - Darbepoetin alfa
Experimental: Vadadustat -
Active Comparator: Darbepoetin alfa -
Treatment: Drugs: Vadadustat
Oral dose administered once daily for =36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Treatment: Drugs: Darbepoetin alfa
Subcutaneous or intravenous dose administered for =36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Query!
Assessment method [1]
0
0
The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (<9.5 versus =9.5 g/dL), geographic region (United States [US] versus European Union [EU] versus Rest of World [ROW]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 [no CHF] or I versus II or III) as covariates.
Query!
Timepoint [1]
0
0
Baseline; Weeks 24 to 36
Query!
Primary outcome [2]
0
0
Median Time to First Major Adverse Cardiovascular Event (MACE)
Query!
Assessment method [2]
0
0
MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [2]
0
0
Up to 176 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
Query!
Assessment method [1]
0
0
The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (<9.5 versus =9.5 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 [no CHF] or I versus II or III) as covariates.
Query!
Timepoint [1]
0
0
Baseline; Weeks 40 to 52
Query!
Secondary outcome [2]
0
0
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
Query!
Assessment method [2]
0
0
MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [2]
0
0
Up to 176 weeks
Query!
Secondary outcome [3]
0
0
Median Time to First Cardiovascular MACE
Query!
Assessment method [3]
0
0
MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [3]
0
0
Up to 176 weeks
Query!
Secondary outcome [4]
0
0
Median Time to First Cardiovascular Death
Query!
Assessment method [4]
0
0
Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [4]
0
0
Up to 176 weeks
Query!
Secondary outcome [5]
0
0
Median Time to First All-cause Mortality
Query!
Assessment method [5]
0
0
Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [5]
0
0
Up to 176 weeks
Query!
Eligibility
Key inclusion criteria
- =18 years of age
- Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for
end-stage kidney disease within 16 weeks prior to Screening
- Mean Screening hemoglobin between 8.0 and <11.0 grams per deciliter (g/dL) (inclusive)
- Serum ferritin =100 nanograms per deciliter (ng/mL) and TSAT =20% during Screening
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Anemia due to a cause other than chronic kidney disease or participants with active
bleeding or recent blood loss
- Red blood cells transfusion within 8 weeks prior to randomization
- Anticipated to recover adequate kidney function to no longer require dialysis
- Uncontrolled hypertension
- Severe heart failure at Screening (New York Heart Association Class IV)
- Acute coronary syndrome (hospitalization for unstable angina, myocardial infarction);
surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral
artery disease (aortic or lower extremity); surgical or percutaneous valvular
replacement or repair; sustained ventricular tachycardia; hospitalization for
congestive heart failure; or stroke within 12 weeks prior to or during Screening.
- Participants meeting the criteria of erythropoiesis-stimulating agent resistance
within 8 weeks prior to or during Screening defined as follows
1. epoetin: > 7700 units/dose three times per week or >23,000 units per week
2. Darbepoetin alfa: >100 micrograms per week (mcg/week)
3. methoxy polyethylene glycol-epoetin beta: >100 micrograms (mcg) every other week
or >200 mcg/month
- Hypersensitivity to Vadadustat, Darbepoetin alfa or any of their excipients
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/03/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
369
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Mexico
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Virginia
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Cordoba
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Corrientes
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Salta
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
San Luis
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Ceará
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Minas Gerais
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Paraná
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio Grande Do Sul
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Santa Catarina
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Sao Paulo
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Baden Wuerttemberg
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Mecklenburg Vorpommern
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Nordrhein Westfalen
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Foggia
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Genova
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Lecco
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Napoli
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Pavia
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Roma
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Siena
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Gangwon-do
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Gyeonggi-do
Query!
Country [42]
0
0
Korea, Republic of
Query!
State/province [42]
0
0
Busan
Query!
Country [43]
0
0
Korea, Republic of
Query!
State/province [43]
0
0
Seoul
Query!
Country [44]
0
0
Mexico
Query!
State/province [44]
0
0
Jalisco
Query!
Country [45]
0
0
Mexico
Query!
State/province [45]
0
0
Michoacán
Query!
Country [46]
0
0
Mexico
Query!
State/province [46]
0
0
Sinaloa
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Golub Dobrzyn
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Lodz
Query!
Country [49]
0
0
Portugal
Query!
State/province [49]
0
0
Leiria
Query!
Country [50]
0
0
Portugal
Query!
State/province [50]
0
0
Loures
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Kemerovo
Query!
Country [52]
0
0
Russian Federation
Query!
State/province [52]
0
0
Krasnoyarsk
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Moscow
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Saint-Petersburg
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
St. Petersburg
Query!
Country [56]
0
0
Ukraine
Query!
State/province [56]
0
0
Brovary
Query!
Country [57]
0
0
Ukraine
Query!
State/province [57]
0
0
Cherkassy
Query!
Country [58]
0
0
Ukraine
Query!
State/province [58]
0
0
Dnipro
Query!
Country [59]
0
0
Ukraine
Query!
State/province [59]
0
0
Ivano-Frankivsk
Query!
Country [60]
0
0
Ukraine
Query!
State/province [60]
0
0
Kharkiv
Query!
Country [61]
0
0
Ukraine
Query!
State/province [61]
0
0
Kyiv
Query!
Country [62]
0
0
Ukraine
Query!
State/province [62]
0
0
Mykolaiv
Query!
Country [63]
0
0
Ukraine
Query!
State/province [63]
0
0
Ternopil
Query!
Country [64]
0
0
Ukraine
Query!
State/province [64]
0
0
Uzhgorod
Query!
Country [65]
0
0
Ukraine
Query!
State/province [65]
0
0
Vinnytsia
Query!
Country [66]
0
0
Ukraine
Query!
State/province [66]
0
0
Zaporizhzhia
Query!
Country [67]
0
0
Ukraine
Query!
State/province [67]
0
0
Zhytomyr
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Akebia Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02865850
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Chief Medical Officer
Query!
Address
0
0
Akebia Therapeutics Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/ct2/show/NCT02865850
Download to PDF